Officials in Cambridge, Mass., last week began reviewing a request by real estate developer Beal Companies to rezone land north of its One Kendall Square mixed-use complex into a separate project that would feature more laboratory and other commercial uses, and less residential space, than the city currently allows.

The proposal seeks to enable Beal "to target both" smaller and larger potential users for the lab space, Peter Spellios, senior vice president and general counsel for the company, told BioRegion News last week.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.